Physician profile
Vu A Phung
NPI 1124290390
$2,864.98
in general payments reported to CMS, 2019-2025
32 companies · $15.85 in 2025
The $15.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.37 · 2022: $232 · 2023: $1,854 · 2024: $665 · 2025: $15.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.67 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $363.29 | 2022-2024 | Darzalex, Tecvayli, Imbruvica |
| Pfizer INC. | $290.81 | 2023-2025 | |
| Astellas Pharma US INC | $230.02 | 2023 | Xtandi |
| Genzyme Corporation | $198.93 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $156.27 | 2023 | Reblozyl, Opdivo |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $117.74 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $116.69 | 2023-2024 | Ojjaara, Shingrix |
| Exelixis INC. | $116.14 | 2023-2024 | Cabometyx |
| Sobi, INC | $113.44 | 2022-2023 | |
| Blueprint Medicines Corporation | $112.36 | 2023-2024 | Ayvakit |
| Cardiovascular Systems INC. | $97.37 | 2019 | |
| Genmab U.S., INC. | $93.14 | 2023-2024 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $83.09 | 2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $73.28 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $66.38 | 2022-2024 | Onivyde, Somatuline Depot |
| Celgene Corporation | $65.93 | 2023-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $58.14 | 2023 | Keytruda, Lynparza |
| Amgen INC. | $56.86 | 2023 | Vectibix, Xgeva, Nplate |
| Incyte Corporation | $42.92 | 2024 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $40.31 | 2023 | Imfinzi, Tagrisso |
| Genentech USA, INC. | $37.00 | 2023-2024 | Venclexta, Perjeta, Herceptin |
| Pharmacosmos Therapeutics INC. | $31.91 | 2023 | Monoferric |
| Lilly USA, LLC | $29.01 | 2022-2023 | Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $25.38 | 2023 | |
| Karyopharm Therapeutics INC. | $25.09 | 2023 | Xpovio |
| Abbvie INC. | $23.26 | 2024 | |
| Fresenius Kabi USA, LLC | $21.70 | 2023 | Stimufend |
| Teva Pharmaceuticals USA, INC. | $16.84 | 2024 | Truxima |
| Jazz Pharmaceuticals INC. | $14.36 | 2023 | |
| Mirati Therapeutics, INC. | $12.83 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $9.49 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.